DRS

OneOncology Partners with Huntsville's Clearview Cancer Institute

Retrieved on: 
Friday, January 12, 2024

NASHVILLE, Tenn. and HUNTSVILLE, Ala., Jan. 12, 2024 /PRNewswire/ -- Clearview Cancer Institute and OneOncology, the fastest-growing national platform for independent oncology practices, announced a finalized partnership to enhance the delivery of cancer services to Alabama communities.

Key Points: 
  • NASHVILLE, Tenn. and HUNTSVILLE, Ala., Jan. 12, 2024 /PRNewswire/ -- Clearview Cancer Institute and OneOncology, the fastest-growing national platform for independent oncology practices, announced a finalized partnership to enhance the delivery of cancer services to Alabama communities.
  • Clearview Cancer Institute is 1 of the 5 largest community oncology practices nationally and the largest in Alabama.
  • Clearview Cancer Institute is one of the five largest community oncology practices nationally and the largest in Alabama.
  • Clearview Cancer Institute has been caring for the lives of Alabamians for over 30 years, offering patients high quality, personalized healthcare close to their own home.

SKYTALE GROUP SERVES AS EXCLUSIVE FINANCIAL ADVISOR TO THE BENGTSON CENTER FOR AESTHETICS AND PLASTIC SURGERY AND SYMMETRY MEDSPA

Retrieved on: 
Monday, January 8, 2024

BCAPS, located in Grand Rapids Michigan, is led by two board-certified plastic surgeons, Drs.

Key Points: 
  • BCAPS, located in Grand Rapids Michigan, is led by two board-certified plastic surgeons, Drs.
  • The Company is one of the leading medical aesthetics and plastic surgery practices in the nation offering a comprehensive suite of plastic surgery, injectables, and aesthetic services.
  • "This transaction quite simply, would have been impossible to navigate and complete without Skytale," states Dr. Bengtson.
  • Skytale Managing Director, Ben Hernandez; Senior Vice President, Tedd Van Gorden; Associate, James Wimpress; Senior Analyst, Christian Guy; and Analyst, Tommy Steis represented BCAPS in the partnership process.

RIVERMARK MEDICAL ANNOUNCES COMPLETION OF EXPANDED INDICATION STUDY FOR THE FLOSTENT™ SYSTEM

Retrieved on: 
Monday, January 8, 2024

MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the successful completion of its RAPID-UR study, an extended indication study that evaluated the use of the Company's FloStent System in patients suffering urinary retention due to BPH. The pilot study included 11 patients, and procedures were performed by Drs. Ingrid Perscky and Ruben Urena at the Pacifica Salud Costa del Este Hospital in Panama City, Panama.

Key Points: 
  • Ingrid Perscky and Ruben Urena at the Pacifica Salud Costa del Este Hospital in Panama City, Panama.
  • Urinary retention (UR) refers to a patient's inability to pass urine, often requiring placement of a temporary indwelling catheter for relief.
  • We are confident this expanded application of the FloStent System will address this critical unmet need."
  • Clinical data from the RAPID-I FIH study, along with results from the expanded indication study, RAPID-UR, will be presented at upcoming Urology congresses.

Evaxion Announces Plan to Implement ADS Ratio Change

Retrieved on: 
Monday, January 8, 2024

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”).

Key Points: 
  • COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”).
  • The ADS Ratio Change is expected to become effective on or about January 22, 2024, U.S. Eastern Time (the “Effective Date”).
  • For the Company’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split and is intended to further support the liquidity in the Company’s ADSs and to enable the Company to regain compliance with the Nasdaq minimum bid price requirement.
  • As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the Ratio Change will have any effect on the liquidity in the Company’s ADSs.

United Aesthetics Alliance Announces Partnership with The Bengtson Center for Aesthetics and Plastic Surgery and Symmetry Medical Spa

Retrieved on: 
Monday, January 8, 2024

United Aesthetics Alliance (“UAA” or “the Company”), a holding company created to consolidate market-leading, clinically differentiated plastic surgery practices and affiliated medical spa service providers, today announced it has recently established a new partnership with The Bengtson Center for Aesthetics & Plastic Surgery (“BCAPS” or “the Practice”).

Key Points: 
  • United Aesthetics Alliance (“UAA” or “the Company”), a holding company created to consolidate market-leading, clinically differentiated plastic surgery practices and affiliated medical spa service providers, today announced it has recently established a new partnership with The Bengtson Center for Aesthetics & Plastic Surgery (“BCAPS” or “the Practice”).
  • Based in Grand Rapids, MI, BCAPS is a premier plastic surgery and aesthetics provider in West Michigan led by two renowned board-certified plastic surgeons, Drs.
  • View the full release here: https://www.businesswire.com/news/home/20240108356764/en/
    Bengtson Center for Aesthetics & Plastic Surgery (Photo: Business Wire)
    “The surgeons and leadership at BCAPS are extremely excited to build a national platform of the top aesthetic practices, which are together developing best practices, in partnership with UAA,” said Dr. Bengtson.
  • Skytale Group acted as the exclusive investment banking advisor to The Bengtson Center for Aesthetics and Plastic Surgery and Symmetry MedSpa in the transaction, with Dykema Gosset PLLC acting as legal advisor.

Mercy's Susan T. Peeler, M.D., and Patricia McMullen, WHNP, named Winners of inaugural Interprofessional Humanism in Healthcare Award

Retrieved on: 
Thursday, January 4, 2024

BALTIMORE, Jan. 4, 2024 /PRNewswire-PRWeb/ -- The Arnold P. Gold Foundation and the American Association of Colleges of Nursing (AACN) have announced the winners of the inaugural AACN-Gold Interprofessional Humanism in Healthcare Award, a new honor that celebrates and elevates the collaboration of physicians and nurses.Susan Todd Peeler, M.D., FACOG, MBA, and Patricia McMullen, PhD, JD, CNS, WHNP-BC, were recognized in December 2023 for their partnership in supporting comprehensive women's healthcare and disseminating best practices on women's health to clinicians across a wide range of disciplines.

Key Points: 
  • Mercy's Susan T. Peeler, M.D., and Patricia McMullen, WHNP, have been named recipients of the inaugural AACN-Gold Interprofessional Humanism in Healthcare Award, a new honor that celebrates and elevates the collaboration of physicians and nurses.
  • The Institute provides routine women's healthcare, as well as services for complex gynecological issues for women of all ages.
  • The new award will be centered each year on a theme, which this year is "Innovations in Interprofessional Collaboration that Drive Humanism in Healthcare."
  • Peeler and McMullen will be presented with the AACN-Gold Interprofessional Humanism in Healthcare Award at the 2024 Gold Humanism Summit in Atlanta, Georgia.

Receipts Depositary Corporation (RDC) Announces First Bitcoin Depositary Receipts for Qualified Institutional Buyers

Retrieved on: 
Thursday, January 4, 2024

NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Receipts Depositary Corporation (RDC) today announced the launch of the first ever Bitcoin depositary receipt (BTC DR). RDC expects to issue the first BTC DRs in transactions exempt from registration under the Securities Act of 1933 to Qualified Institutional Buyers (QIBs) in the coming weeks. BTC DRs are now available on an ongoing basis for issuance to QIBs.

Key Points: 
  • NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Receipts Depositary Corporation (RDC) today announced the launch of the first ever Bitcoin depositary receipt (BTC DR).
  • RDC expects to issue the first BTC DRs in transactions exempt from registration under the Securities Act of 1933 to Qualified Institutional Buyers (QIBs) in the coming weeks.
  • BTC DRs follow the same construction as American Depositary Receipts (ADRs), and like ADRs, BTC DRs operate within US-regulated market infrastructure and are cleared through The Depository Trust Company (DTC ).
  • "Depositary receipts are a simple solution to complex access problems for institutional investors," said Matthew Taback, Senior Market Maker, GTS .

Moonwalk Biosciences Launches with $57 Million in Financing to Advance a New Class of Precision Epigenetic Medicines

Retrieved on: 
Thursday, January 4, 2024

The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.

Key Points: 
  • The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.
  • View the full release here: https://www.businesswire.com/news/home/20240104793936/en/
    Moonwalk Biosciences founding team (from left to right): Alex Aravanis, CEO, Justin Valley, COO, Elaine Cheung, CBO, Arash Jamshidi, President & CTO.
  • Moonwalk is the first company that couples an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases.
  • We look forward to what new innovations Moonwalk can advance in epigenetic engineering,” said Robert Nelsen, Managing Director and Co-Founder, ARCH Venture Partners.

Ascend Vision Partners Joins Forces with Bay Area Retina Consultants to bring much needed Uveitis and Retina services to the Greater Tampa Bay area

Retrieved on: 
Thursday, January 4, 2024

ORLANDO, Fla., Jan. 3, 2024 /PRNewswire/ -- Ascend Vision Partners ("AVP"), the leading provider of business services for eye care practices across the southeastern U.S., formed a strategic partnership with Bay Area Retina Consultants , a well-established and respected retina group serving the Greater Tampa Bay area in Florida.

Key Points: 
  • ORLANDO, Fla., Jan. 3, 2024 /PRNewswire/ -- Ascend Vision Partners ("AVP"), the leading provider of business services for eye care practices across the southeastern U.S., formed a strategic partnership with Bay Area Retina Consultants , a well-established and respected retina group serving the Greater Tampa Bay area in Florida.
  • This venture expands AVP's footprint in the area allowing them to further provide exceptional care to Pasco, Pinellas and Hillsborough County residents.
  • Chad Tomlinson, Chief Growth Officer at Ascend Vision Partners, expressed his excitement about this west coast expansion: "Dr. Mines and Menosky have well established roots in the community.
  • Their excellence in eyecare and their accessible locations allow for greater patient access in the Greater Tampa Bay market."

Molecular Diagnostics Research That Could Transform Healthcare Featured in the January Issue of ADLM's The Journal of Applied Laboratory Medicine

Retrieved on: 
Wednesday, January 3, 2024

This special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) The Journal of Applied Laboratory Medicine highlights the latest research in this field that could advance care for conditions ranging from infectious diseases to inherited disorders.

Key Points: 
  • This special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) The Journal of Applied Laboratory Medicine highlights the latest research in this field that could advance care for conditions ranging from infectious diseases to inherited disorders.
  • The COVID-19 pandemic is the most striking recent example of the central role of molecular diagnostics in global health.
  • And pandemic management isn't the only area of infectious disease testing that molecular diagnostic technology is revolutionizing.
  • Broadening access to personalized medicine is another goal of modern healthcare that wouldn't be possible without molecular diagnostics.